SLC6A3 and Parkinson disease: We first described disease-specific biomechanical abnormalities comparing PD patients with age- and gender-matched healthy subjects; we further showed the effect of a dopaminergic therapy (i.e., levodopa) and compared kinematic resultants of APA with putaminal DAT binding values.